Is Dynavax Technologies Corporation (DVAX) overvalued? · rev $277.2M
Dynavax Technologies Corporation (DVAX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Dynavax Technologies Corporation (DVAX) looks expensive on cached numbers — not a short thesis.
Latest reported DVAX revenue for 2024-12-31 was $277.2M. Net income was $27.3M. Revenue was up 19.4% from 2023-12-31 to 2024-12-31. DVAX currently screens at market cap $1.82B.
DVAX currently screens at market cap $1.82B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DVAX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DVAX stock page for the full model, not this heading.
Not investment advice.